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INTRODUCTION
Schizophrenia is characterized by profound disturbances in
cognition, emotion, and social functioning. Catechol-O-
methyl transferase (COMT) is the important enzyme for
the metabolism of monoamines, which play important part
in the pathogenesis of schizophrenia. COMT exists in high
and low activity forms. The low activity form was found to
be an amino acid substitution (Val-108-Met), which reduces
the thermostability of the enzyme. This genetic polymor-
phism has been reported to be associated with schizophre-
nia and its associated clinical features (Li et al., 1996).
Shifman et al. (2002) reported a highly significant asso-
ciation between schizophrenia and a COMT haplotype in a
large case–control sample. This haplotype included two non-
coding single-nucleotide polymorphisms (SNPs) at either
end of the COMT gene in addition to the valine-methionine
(Val0Met) polymorphism. Bray et al. (2003) showed that
COMT variants other than the Val0Met change are of func-
tional importance to the human brain and that the haplotype
implicated in schizophrenia susceptibility is likely to exert
its effect, either directly or indirectly, by down-regulating
COMT gene expression. However, little is known about the
impact of such COMT variants upon the clinical manifes-
tations and neurocognitive functions in patients with schizo-
phrenia. Given the role of COMT alleles in physiology of
prefrontal cognition and that the COMT gene variants are
susceptible to schizophrenia (Egan et al., 2001), we exam-
ined the specific clinical manifestations and neurocognitive
profile of the patients with the identified COMT SNP
rs165599 genotypes in a group of Chinese patients with
schizophrenia.
MATERIALS AND METHODS
All patients met the DSM–IV (American Psychiatric Asso-
ciation, 1994) criteria of schizophrenia. Consensus diagno-
sis was made independently by two authors of the present
study (EFCC, RYLC) by face-to-face interview using the
Structured Clinical Interview for DSM–IV. All patients were
taking conventional antipsychotic medication together with,
in some cases, anticholinergic medication (benzhexol in all
subjects). Patients with a history of physical illness involv-
ing the central nervous system, substance and0or alcohol
abuse were excluded.
Patients genomic DNA was collected by standard method.
The primers were designed by Primer3 program basic on
the human genomic sequence from the public databases
(National Institute of Health, 2004). The sequences were:
59-CATTCAAAGCTCCCCTTGAC-39 and 59GGGAGTA
GGGAAGGAGATGC-39. PCR was performed by using
100ng genomic DNA, 1x buffer, 1.5mM MgCl2, 0.2mM
dNTPs, 0.25mM of each primer and 1U Taq (ABgene). Run-
ning conditions consists 35 cycles of 948C denaturing for
1 min, 568C annealing for 1 min and 728C extension for
another 1 min. The PCR product (301bp) was then digested
by the restriction enzyme MspI (New England BioLab).
The A allele gives fragment of 301bp, while the G allele
gives fragments of 166 and 135bp. The DNA fragments
were detected by standard electrophoresis method. Perfect
agreement (100%) on the genotyping processing was estab-
lished between two laboratory technicians on the same
sample.
Clinical symptoms were assessed using the Positive and
Negative Syndrome Scale (PANSS; Kay et al., 1987). The
details of the complete procedure for each test are reported
elsewhere (Chan et al., 2001; Halperin et al., 1991). Back-
ground cognition was assessed with the Wechsler Adult In-
telligence Test–III Scale (WAIS–III; Wechsler, 1997a).
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Sustained attention was assessed by the Continuous Perfor-
mance Test (Halperin et al., 1991). Verbal and visual mem-
ory was assessed by the Logical Memory Test and Visual
Reproduction Test from the Wechsler Memory Scale–III
(WMS–III; Wechsler, 1997b). Working memory was
assessed by the Letter-Number Span Test (Gold et al., 1997)
and 2-back test (Callicott et al., 1998). Executive function
was assessed by verbal fluency and the Stroop Test.
The university and the corresponding hospital ethics com-
mittees approved the research plan and the recruitment pro-
cedure of the subjects with schizophrenia. Informed consent
was obtained from all the subjects prior to the testing ses-
sion and blood taking in accordance with the Declaration of
Helsinki.
SPSS for window version 11.0 was used for statistical
analysis. We computed a standardized score (z score) with
the normative data from our laboratory. Multiple univariate
analysis of covariance (ANCOVA) controlling for age, in-
tellectual functioning, medication and duration of illness
would be made whenever appropriate. Another set of non-
parametric test of Kruskal-Wallis H Test would also be con-
ducted to check with the consistency of the results. Statistical
significance was considered to be attained at p , .05.
RESULTS
A total of 36 patients (31 men, 5 women) were recruited
and completed the full set of neurocognitive tests. The demo-
graphics of the sample are summarized in Table 1. No sig-
nificant differences were found among the groups in terms
of education level, gender proportion, and diagnosis.
Multiple univariate ANCOVA controlling for age, dura-
tion of illness and medication dosage was conducted.
Significant difference was found in negative symptoms
[F(2,33) 5 4.4, p 5 0.026; Table 2]. Post-hoc analysis
showed that the patients with G0G genotype exhibited the
most severe negative symptoms. Patients with A0A tended
to demonstrate lesser negative symptoms. No other signif-
icant differences were found between the subgroups in other
clinical symptoms as well as neurological signs. Non-
parametric Kruskal-Wallis H tests demonstrated the same
pattern.
Significant differences were also found in Visual Repro-
duction [F(2,31) 5 6.129, p 5 .006], Stroop Test [F(2,31) 5
3.657, p 5 .038], and 2-back reaction time for correct
response [F(2,31) 5 3.987, p 5 .029]. Post-hoc analyses
showed that patients with G0G genotype performed signif-
icantly worse than patients with A0G in Visual Reproduc-
tion (t 5 3.462, p 5 .002), 2-Back reaction time for correct
response (t 5 1.962, p 5 .05), and exhibited significantly
more interference in Stroop Test (t 5 2.679, p 5 .012).
Similar findings were replicated by Kruskal-Wallis H tests.
DISCUSSION
The present study identified a differential pattern of clinical
and neurocognitive profiles in patients with different COMT
SNP rs165599 genotypes. The findings are summarized as
follows:
1. Patients with COMT SNP G0G genotype exhibited the
most severe negative symptoms as compared with those
with COMT SNP A0A.
2. General impairments were observed in different sub-
groups of COMT SNP genotypes. Memory impairments
and prefrontal executive function impairments were more
pronounced in patients with COMT SNP G0G genotype.
COMT SNP rs165599 is a SNP with recent interest. It
has not been widely studied. From the molecular point of
view, it is at the downstream position of the COMT gene.
There was evidence of the presence of this SNP transcript
in human brain. This SNP (G0G) was found to be over-
represented in schizophrenia and also demonstrated to have
reduction in COMT expression (Bray et al., 2003). Thus it
is speculated that this SNP polymorphism (or other nearby
polymorphism in linkage disequilibrium) may involve in
COMT gene regulation rendering susceptibility of schizo-
phrenia and its associated clinical and neurocognitive impair-
ment. The present study provides the first preliminary data
on the impact of the COMT SNP rs165599 genotypes upon
the clinical manifestations and neurocognitive performance
in a group of Chinese patients with schizophrenia. Further
Table 1. Demographics of the three COMT SNP genotype subgroups
A0A
(n 5 11)
A0G
(n 5 13)
G0G
(n 5 12)
Age (years) 39 (8.9) 44.8 (6.5) 44.6 (9.1)
Education (years) 9.6 (2.3) 8.1 (4.1) 8.7 (2.1)
Duration of illness (years) 15.9 (9.4) 22.1 (7.2) 21.9 (8.8)
Gender (M:F) 10:1 13:0 8:4
Medication (Chlorpromazine equivalence mg0day) 747.33 (576.69) 2072.55 (2056.22) 1475.78 (1092.85)
Diagnosis
Disorganized type 2 1 0
Paranoid type 8 10 11
Residual type 1 2 1
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studies recruiting a larger sample and different ethnic groups
are indicated to validate the present findings.
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Table 2. Summary scores of clinical and cognitive profiles among the three COMT SNP genotype subgroups
Genotype of COMT SNP rs165599
Profiles A0A A0G G0G F(2,31) p
Clinical profiles
PANSS positive symptoms 18.17 (9.09) 14.82 (6.46) 16.00 (4.21) 0.234 n.s.
PANSS negative symptoms 13.00 (5.90) 13.36 (5.20) 19.33 (4.87) 4.4 .026
PANSS global psychopathology 34.50 (9.77) 33.09 (8.57) 35.67 (8.41) 0.308 n.s.
PANSS social impulsivity 3.67 (1.63) 4.18 (2.32) 5.00 (2.78) 0.376 n.s.
Cognitive profiles
Information 14.73 (4.50) 14.00 (5.05) 11.33 (3.37) 1.959 n.s.
CPT correct response 357.91 (57.36) 362.62 (35.29) 350.75 (51.79) 0.184 n.s.
CPT commission error 28.27 (37.50) 28.62 (25.08) 31.75 (34.14) 0.045 n.s.
Logical Memory (immediate) 7.45 (3.96) 5.62 (2.43) 4.17 (2.41) 2.508 n.s.
Logical Memory (delay) 3.45 (2.84) 3.62 (2.66) 2.75 (2.26) 0.164 n.s.
Visual Reproduction (immediate) 16.18 (2.52) 18.46 (3.31) 13.25 (4.62) 6.129 .006
Visual Reproduction (delay) 12.18 (5.88) 15.23 (3.77) 11.00 (6.27) 1.919 n.s.
Letter-Number span longest item 4.09 (1.04) 3.69 (1.49) 3.67 (0.78) 0.057 n.s.
2-back correct % 25.82 (13.31) 31.08 (12.67) 22.67 (11.98) 1.469 n.s.
2-back correct reaction time (ms) 776.55 (269.73) 1155.23 (255.04) 905.25 (372.79) 3.987 .029
Verbal Fluency 15.55 (5.07) 14.46 (5.22) 11.42 (3.60) 1.383 n.s.
Stroop Interference 244.82 (21.19) 234.45 (17.94) 257.42 (20.50) 3.657 .038
204 R.C.K. Chan et al.
